Summary
The evaluated claims are about market exclusivity, patents, and regulatory exclusivity timelines, but the provided FDA label excerpts do not address these topics. Therefore, these claims cannot be verified as supported by the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Ticagrelor’s market exclusivity is not one single date.
The provided FDA prescribing information excerpts do not mention market exclusivity or any exclusivity timeline structure (single vs multiple dates).
Intellectual property protection for ticagrelor can include both patents that protect specific inventions and regulatory exclusivities that can restrict generic entry even after a patent case ends.
The provided label excerpts do not discuss patents, regulatory exclusivities, or generic entry restrictions.
The provided information does not include specific patent or exclusivity expiry dates needed to answer when ticagrelor’s protection expires with certainty.
While this may be true generally, the question here is whether it is supported by the supplied FDA label excerpts; the excerpts do not provide patent/exclusivity expiry dates, and the claim is not explicitly supported in the label text.
To determine the end date for generic competition for ticagrelor, it is necessary to check the exact patents and any granted regulatory exclusivities in the relevant country (typically the US or EU).
The provided FDA prescribing information excerpts do not address how to determine generic competition end dates, or the role of patents/regulatory exclusivities.
The patent or regulatory exclusivity term dates for ticagrelor vary by jurisdiction and by which patent or exclusivity term is being considered.
The provided label excerpts do not discuss jurisdictional variation or different exclusivity/patent term structures.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs, including ticagrelor.
The supplied FDA label excerpts do not mention DrugPatentWatch.com or any third-party tracking service.
DrugPatentWatch.com can be used to see whether ticagrelor protection is listed as still active or when it is scheduled to end.
The supplied FDA label excerpts do not mention DrugPatentWatch.com or describe its contents/functionality.
Even if one ticagrelor patent expires, other patents covering different aspects such as formulations, specific dosage forms, manufacturing methods, or crystalline forms can keep exclusivity alive.
The provided FDA prescribing information excerpts do not discuss patents covering formulations/dosage forms/manufacturing methods/crystalline forms, or how such patents affect exclusivity/generic entry.
Separate regulatory exclusivities can delay approval or launch of generics depending on the country for ticagrelor.
The provided FDA label excerpts do not discuss regulatory exclusivities delaying generic approval/launch or country-dependent effects.
Contradictions
Important Omissions
Any FDA label-supported information regarding patents, market exclusivity, or regulatory exclusivity timelines for BRILINTA/ticagrelor.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily about legal/regulatory exclusivity rather than prescribing, dosing, contraindications, warnings, interactions, or safety monitoring. The supplied label excerpts do not support these claims, but the claims do not directly instruct patient use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about market/patent/regulatory exclusivity timelines and third-party tracking are not addressed in the supplied FDA label excerpts and therefore cannot be verified as supported by on-label prescribing information.
Suggested Improvement
Remove or qualify exclusivity/patent/timeline assertions unless supported by the provided FDA labeling text; alternatively, cite specific FDA label sections that actually discuss exclusivity or patent-related information (if present in the full label provided).